RiboGene Inc., a bio-instrumentation company, has raised $2.25million in venture capital from Kleiner, Perkins, Caufield &Byers and Sierra Ventures. Including this round, the twoventure firms have invested more than $3.6 million in RiboGenesince its founding in May 1989.

RiboGene of Menlo Park, Calif., is developing instrumentationfor cell-free protein synthesis as a more rapid alternative togenetic engineering or solid state peptide synthesis.

The funds will be used to manufacture and market anautomated bench-top instrument, which will be commerciallyavailable in the second half of 1992.

RiboGene in June 1990 signed an agreement with the Instituteof Protein Research in Moscow giving RiboGene worldwiderights to U.S. and international patents held by the Institutefor the cell-free production of proteins. The Institute has a 15percent ownership position in RiboGene.

(c) 1997 American Health Consultants. All rights reserved.